Publications of Roland T. Ullrich

Mittenbühler, M.; Saedler, K.; Nolte, H.; Kern, L.; Zhou, J.; Qian, S.-B.; Meder, L.; Ullrich, R. T.; Brüning, J. C.; Wunderlich, F. T.: Hepatic FTO is dispensable for the regulation of metabolism but counteracts HCC development in vivo. Molecular Metabolism 42, 101085 (2020)

Fernandez-Cuesta, L.; Sun, R.; Menon, R.; George, J.; Lorenz, S.; Meza-Zepeda, L. A.; Peifer, M.; Plenker, D.; Heuckmann, J. M.; Leenders, F. et al.; Zander, T.; Dahmen, I.; Koker, M.; Schöttle, J.; Ullrich, R. T.; Altmüller, J.; Becker, C.; Nürnberg, P.; Seidel, H.; Böhm, D.; Göke, F.; Ansen, S.; Russell, P. A.; Wright, G. M.; Wainer, Z.; Solomon, B.; Petersen, I.; Clement, J. H.; Sänger, J.; Brustugun, O. T.; Helland, A.; Solberg, S.; Lund-Iversen, M.; Büttner, R.; Wolf, J.; Brambilla, E.; Vingron, M.; Perner, S.; Haas, S. A.; Thomas, R. K.: Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology 16, 7 (2015)

Schöttle, J.; Chatterjee, S.; Volz, C.; Siobal, M.; Florin, A.; Rokitta, D.; Hinze, Y.; Dietlein, F.; Plenker, D.; König, K. et al.; Albus, K.; Heuckmann, J. M.; Rauh, D.; Franz, T.; Neumaier, B.; Fuhr, U.; Heukamp, L. C.; Ullrich, R. T.: Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget 6 (36), pp. 38458 - 38468 (2015)

Chatterjee, S.; Wieczorek, C.; Schöttle, J.; Siobal, M.; Hinze, Y.; Franz, T.; Florin, A.; Adamczak, J. M.; Heukamp, L. C.; Neumaier, B. et al.; Ullrich, R. T.: Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Research 74 (10), pp. 2816 - 2824 (2014)

Fernandez-Cuesta, L.; Plenker, D.; Osada, H.; Sun, R.; Menon, R.; Leenders, F.; Ortiz-Cuaran, S.; Peifer, M.; Bos, M.; Daßler, J. et al.; Malchers, F.; Schöttle, J.; Vogel, W.; Dahmen, I.; Koker, M.; Ullrich, R. T.; Wright, G. M.; Russell, P. A.; Wainer, Z.; Solomon, B.; Brambilla, E.; Nagy-Mignotte, H.; Moro-Sibilot, D.; Brambilla, C. G.; Lantuejoul, S.; Altmüller, J.; Becker, C.; Nürnberg, P.; Heuckmann, J. M.; Stoelben, E.; Petersen, I.; Clement, J. H.; Sänger, J.; Muscarella, L. A.; la Torre, A.; Fazio, V. M.; Lahortiga, I.; Perera, T.; Ogata, S.; Parade, M.; Brehmer, D.; Vingrom, M.; Heukamp, L. C.; Buettner, R.; Zander, T.; Wolf, J.; Perner, S.; Ansen, S.; Haas, S. A.; Yatabe, Y.; Thomas, R. K.: CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery 4 (4), pp. 415 - 422 (2014)

Malchers, F.; Dietlein, F.; Schöttle, J.; Lu, X.; Nogova, L.; Albus, K.; Fernandez-Cuesta, L.; Heuckmann, J. M.; Gautschi, O.; Diebold, J. et al.; Plenker, D.; Gardizi, M.; Er, M. S.; Bos, M.; Seidel, D.; Leenders, F.; Richters, A.; Peifer, M.; Florin, A.; Mainkar, P. S.; Karre, N.; Chandrasekhar, S.; George, J.; Silling, S.; Rauh, D.; Zander, T.; Ullrich, R. T.; Reinhardt, H. C.; Ringeisen, F.; Buettner, R.; Heukamp, L. C.; Wolf, J.; Thomas, R. K.: Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery 4 (2), pp. 246 - 257 (2014)

Rothe, A.; Jachimowicz, R. D.; Borchmann, S.; Madlener, M.; Keßler, J.; Reiners, K. S.; Sauer, M.; Hansen, H. P.; Ullrich, R. T.; Chatterjee, S. et al.; Borchmann, P.; Yazaki, P.; Koslowsky, T. C.; Engert, A.; Heukamp, L. C.; Hallek, M.; Von Strandmann, E. P.: The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. International Journal of Cancer 134 (12), pp. 2829 - 2840 (2014)

Chatterjee, S.; Heukamp, L. C.; Siobal, M.; Schöttle, J.; Wieczorek, C.; Peifer, M.; Frasca, D.; Koker, M.; König, K.; Meder, L. et al.; Rauh, D.; Buettner, R.; Wolf, J.; Brekken, R. A.; Neumaier, B.; Christofori, G.; Thomas, R. K.; Ullrich, R. T.: Tumor vegf:vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation 123 (4), pp. 1732 - 1740 (2013)

Heukamp, L. C.; Thor, T.; Schramm, A.; De Preter, K.; Kumps, C.; de Wilde, B.; Odersky, A.; Peifer, M.; Lindner, S.; Spruessel, A. et al.; Pattyn, F.; Mestdagh, P.; Menten, B.; Kuhfittig-Kulle, S.; Kuenkele, A.; Koenig, K.; Meder, L.; Chatterjee, S.; Ullrich, R. T.; Schulte, S.; Vandesompele, J.; Speleman, F.; Buettner, R.; Eggert, A.; Schulte, J. H.: Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science Translational Medicine 4 (141), 141ra91 (2012)

Kobe, C.; Scheffler, M.; Holstein, A.; Zander, T.; Nogova, L.; Lammertsma, A. A.; Boellaard, R.; Neumaier, B.; Ullrich, R. T.; Dietlein, M. et al.; Wolf, J.; Kahraman, D.: Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging 39 (7), pp. 1117 - 1127 (2012)

Sos, M. L.; Dietlein, F.; Peifer, M.; Schöttle, J.; Balke-Want, H.; Müller, C.; Koker, M.; Richters, A.; Heynck, S.; Malchers, F. et al.; Heuckmann, J. M.; Seidel, D.; Eyers, P. A.; Ullrich, R. T.; Antonchik, A. P.; Vintonyak, V. V.; Schneider, P. M.; Ninomiya, T.; Waldmann, H. H.; Büttner, R.; Rauh, D.; Heukamp, L.; Thomas, R. K.: A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 109 (42), pp. 17034 - 17039 (2012)

Ullrich, R. T.; Zander, T.; Wolf, J.; Hallek, M.: Personalisierte Therapie von Lungenkrebs. Deutsche Medizinische Wochenschrift 137 (42), pp. 2179 - 2180 (2012)

Galldiks, N.; Kracht, L. W.; Dunkl, V.; Ullrich, R. T.; Vollmar, S.; Jacobs, A. H.; Fink, G. R.; Schroeter, M.: Imaging of non-or very subtle contrast-enhancing malignant gliomas with [ 11C]-methionine positron emission tomography. Molecular Imaging 10 (6), pp. 453 - 459 (2011)

Kahraman, D.; Scheffler, M.; Zander, T.; Nogova, L.; Lammertsma, A. A.; Boellaard, R.; Neumaier, B.; Ullrich, R. T.; Holstein, A.; Dietlein, M. et al.; Wolf, J.; Kobe, C.: Quantitative analysis of response to treatment with Erlotinib in advanced non–small cell lung cancer using 18F-FDG and 39-deoxy-39-18F-fluorothymidine PET. Journal of Nuclear Medicine 52 (12), pp. 1 - 7 (2011)

Ullrich, R. T.; Jikeli, J. F.; Diedenhofen, M.; Böhm-Sturm, P.; Unruh, M.; Vollmar, S.; Hoehn, M.: In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS ONE 6 (5), p. e19592 - e19592 (2011)

Waerzeggers, Y.; Ullrich, R. T.; Monfared, P.; Viel, T.; Weckesser, M.; Stummer, W.; Schober, O.; Winkeler, A.; Jacobs, A. H.: Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. British Journal of Radiology 84 (Spec. Iss. 2), pp. S179 - S195 (2011)

Zander, T.; Scheffler, M.; Nogova, L.; Kobe, C.; Engel-Riedel, W.; Hellmich, M.; Papachristou, I.; Toepelt, K.; Draube, A.; Heukamp, L. et al.; Buettner, R.; Ko, Y. D.; Ullrich, R. T.; Smit, E.; Boellaard, R.; Lammertsma, A. A.; Hallek, M.; Jacobs, A. H.; Schlesinger, A.; Schulte, K.; Querings, S.; Stoelben, E.; Neumaier, B.; Thomas, R. K.; Dietlein, M.; Wolf, J.: Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. Journal of Clinical Oncology 29 (13), pp. 1701 - 1708 (2011)

Bill, A.; Schmitz, A.; Albertoni, B.; Song, J.-N.; Heukamp, L. C.; Walrafen, D.; Thorwirth, F.; Verveer, P. J.; Zimmer, S.; Meffert, L. et al.; Schreiber, A.; Chatterjee, S.; Thomas, R. K.; Ullrich, R. T.; Lang, T.; Famulok, M.: Cytohesins are cytoplasmic ErbB receptor activators. Cell 143 (2), pp. 201 - 211 (2010)

Galldiks, N.; Kracht, L. W.; Burghaus, L.; Ullrich, R. T.; Backes, H.; Brunn, A.; Heiss, W.-D.; Jacobs, A. H.: Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Molecular Imaging 9 (1), pp. 40 - 46 (2010)

Galldiks, N.; Ullrich, R.; Schroeter, M.; Fink, G. R.; Kracht, L. W.: Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. European Journal of Nuclear Medicine and Molecular Imaging 37 (1), pp. 84 - 92 (2010)